TAK1 Is Required for Survival of Mouse Fibroblasts Treated with TRAIL, and Does So by NF-κB Dependent Induction of cFLIPL

• Published in: PloS one Vol. 5; no. 1; p. e8620
• Main Authors: Lluis, Josep Maria, Nachbur, Ulrich, Cook, Wendy Diane, Gentle, Ian Edward, Moujalled, Donia, Moulin, Maryline, Wong, Wendy Wei-Lynn, Khan, Nufail, Chau, Diep, Callus, Bernard Andrew, Vince, James Edward, Silke, John, Vaux, David Lawrence
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 08-01-2010
• Subjects: Activation; Apoptosis; Biochemistry; Biochemistry/Cell Signaling and Trafficking Structures; Cell Biology/Cell Signaling; Cell Biology/Cellular Death and Stress Responses; Cell death; Cloning; Colorectal cancer; Cytokines; Ectopic expression; Embryo fibroblasts; Embryos; Ethics; Fibroblasts; IKK2 protein; JNK protein; Kinases; Leukemia; Ligands; Mortality; NF-κB protein; Prostate cancer; Proteins; Receptors; Signal transduction; Signaling; Survival; TAK1 protein; TRAIL protein; Tumor cells; Tumor necrosis factor; Tumor necrosis factor-TNF
• DOI: 10.1371/journal.pone.0008620
• EISSN: 1932-6203

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known as a “death ligand”—a member of the TNF superfamily that binds to receptors bearing death domains. As well as causing apoptosis of certain types of tumor cells, TRAIL can activate both NF-κB and JNK signalling pathways. To determine the role of TGF-β-Activated Kinase-1 (TAK1) in TRAIL signalling, we analyzed the effects of adding TRAIL to mouse embryonic fibroblasts (MEFs) derived from TAK1 conditional knockout mice. TAK1−/− MEFs were significantly more sensitive to killing by TRAIL than wild-type MEFs, and failed to activate NF-κB or JNK. Overexpression of IKK2-EE, a constitutive activator of NF-κB, protected TAK1−/− MEFs against TRAIL killing, suggesting that TAK1 activation of NF-κB is critical for the viability of cells treated with TRAIL. Consistent with this model, TRAIL failed to induce the survival genes cIAP2 and cFlipL in the absence of TAK1, whereas activation of NF-κB by IKK2-EE restored the levels of both proteins. Moreover, ectopic expression of cFlipL, but not cIAP2, in TAK1−/− MEFs strongly inhibited TRAIL-induced cell death. These results indicate that cells that survive TRAIL treatment may do so by activation of a TAK1–NF-κB pathway that drives expression of cFlipL, and suggest that TAK1 may be a good target for overcoming TRAIL resistance.